The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis

Gut

Volumn 46, Issue 1, 2000, Pages 64-72

  Pitcher, M C L ^a   Beatty, E R ^a   Cummings, J H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bacteria; Colitis; Fermentation; Salicylate; Sulphate; Sulphide

Indexed keywords

BUTYRIC ACID; HYDROGEN SULFIDE; MESALAZINE; SULFATE;

ADULT; ARTICLE; BACTERIAL COUNT; BACTERIAL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FECES; FEMALE; FERMENTATION; HUMAN; MALE; PRIORITY JOURNAL; SULFATE REDUCING BACTERIUM; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; FEMALE; HUMANS; HYDROGEN SULFIDE; MALE; MESALAMINE; MIDDLE AGED; SULFATES; SULFUR-REDUCING BACTERIA;

EID: 0034027081     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.1.64     Document Type: Article

References (77)

1. 1 Satsangi J, Jewell DP, Rosenberg WMC, et al. Genetics of inflammatory bowel disease. Gut 1994;35:696-700.
2. 2 Ohkusa T, Yamada M, Takenaga T, et al. Protective effect of metronidazole in experimental ulcerative colitis induced by dextran sulfate sodium. Jpn J Gastroenterol 1987;84:2337-46.
3. 3 Onderdonk AB, Hermos JA, Dzink JL, et al. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978;74:521-6.
4. 4 Onderdonk AB, Bartlett JG. Bacteriological studies of experimental ulcerative colitis. Am J Clin Nutr 1979;32: 258-65.
5. 5 Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
6. 6 Sartor RB. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol 1996;12:327-33.
7. 7 Frankel WL, Zhang W, Singh A, et al. Mediation of the trophic effects of short-chain fatty acids on the rat jejunum and colon. Gastroenterology 1994;106:375-80.
8. 8 Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in the human large intestine, portal, hepatic, and venous blood. Gut 1987;28:1221-7.
9. 9 Roediger WEW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980;21:793-8.
10. 10 Roediger WEW. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982;83: 424-9.
11. 11 Chapman MAS, Grahn MF, Boyle MA, et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 1994;35:73-6.
12. 12 Clausen MR, Mortensen PB. Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. Gut 1995;37:684-9.
13. 13 Finnie IA, Taylor BA, Rhodes JM. Ileal and colonic epithelial cell metabolism in ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut 1993;34:1552-8.
14. 14 Roediger WEW. The colonic epithelium in ulcerative colitis: an energy deficient disease? Lancet 1980;ii:712-15.
15. 15 Den Hond E, Hiele M, Ghoos Y, et al. In vivo colonic butyrate metabolism in extensive ulcerative colitis [abstract]. Gastroenterology 1996;110:A893.
16. 16 Simpson EJ, Chapman MAS, Dawson J, et al. In vivo metabolism of colonically administered butyrate in quiescent human ulcerative colitis [abstract]. Gut 1998;42:A42.
17. 17 Cummings JH. Short-chain fatty acid enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol Hepatol 1997;9:149-53.
18. 18 Breuer RI, Christ ML, Lashner BA, et al. Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo-controlled clinical trial. Gut 1997;40: 485-91.
19. 19 Roediger WEW, Duncan A, Kapaniris O, et al. Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 1993; 104:802-9.
20. 20 Roediger WEW, Duncan A, Kapaniris O, et al. Sulphide impairment of substrate oxidation in rat colonocytes: a biochemical basis for ulcerative colitis? Clin Sci 1993;85:1-5.
21. 21 Moore JW, Millard S, Babidge W, et al. Hydrogen sulphide produces diminished fatty acid oxidation in the rat colon in vivo: implications for ulcerative colitis. Aust N Z J Surg 1997;67:245-9.
22. 22 Aslam M, Batten JJ, Florin THJ, et al. Hydrogen sulphide induced damage to the colonic mucosal barrier in the rat [abstract]. Gut 1992;33:F274.
23. 23 Pitcher MCL, Cummings JH. Hydrogen sulphide:a bacterial toxin in ulcerative colitis? Gut 1996;39:1-4.
24. 24 Postgate JR. The sulphate-reducing bacteria. Cambridge: Cambridge University Press, 1984.
25. 25 Gibson GR. A review: physiology and ecology of sulphate-reducing bacteria. J Appl Bacteriol 1990;69:769-97.
26. 26 Gibson GR, Macfarlane GT, Cummings JH. Occurrence of sulphate-reducing bacteria in human faeces and the relationship of dissimilatory sulphate reduction to methanogenesis in the large gut. J Appl Bacteriol 1988;65:103-11.
27. 27 Gibson GR, Cummings JH, Macfarlane GT, et al. Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut 1990;31:679-83.
28. 28 Fox JG, Dewhirst FE, Fraser GJ, et al. Intracellular Campylobacter-like organism from ferrets and hamsters with proliferative bowel disease is a Desulfovibrio sp. J Clin Microbiol 1994;32:1229-37.
29. 29 Gebhart CJ, Barns SM, McOrist S, et al. Ileal Symbiont Intracellularis, an obligate intracellular bacterium of porcine intestines showing a relationship to Desulfovibrio species. Int J Syst Bacteriol 1993;43:533-8.
30. 30 Azad Kahn AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;ii:892-5.
31. 31 van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the therapeutic active moiety of sulphasalazine. Gut 1980;21: 632-5.
32. 32 Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955;2:1041-8.
33. 33 Ruddell WSJ, Dickinson RJ, Dixon MF, et al. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980;21:885-9.
34. 34 Segal I, Walker ARP, Lord S, et al. Breath methane and large bowel cancer risk in contrasting African populations. Gut 1988;29:608-13.
35. 35 Macfarlane GT, Gibson GR. Sulphate-reducing bacteria. In Anaerobic microbiology: a practical approach. Oxford: Oxford University Press, 1991:201-22.
36. 36 Cline JD. Spectrophotometric determination of hydrogen sulphide in natural waters. Limnol Oceanogr 1969;14:454-8.
37. 37 Strocchi A, Furne JK, Levitt MD. A modification of the methylene blue method to measure bacterial sulfide production in feces. J Microbiol Method 1992;15:75-82.
38. 38 Joørgensen BB. A comparison of methods for the quantification of bacterial sulfate reduction in coastal marine sediments. I. Measurements with radiotracer techniques. Geomicrobiol J 1978;1:11-27.
39. 39 Florin T, Neale G, Gibson GR, et al. Metabolism of dietary sulphate: absorption and excretion in humans. Gut 1991;32:766-73.
40. 40 Gibson GR, Cummings JH, Macfarlane GT. Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol Ecol 1991;86:103-12.
41. 41 El Oufir L, Flourié B, Bruley des Varannes S, et al. Relationships between transit time, fermentation products and hydrogen-consuming flora in healthy humans. Gut 1996; 38:870-7.
42. 42 Gorbach SL, Nahas L, Plaut AG, et al. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy. Gastroenterology 1968;54:575-87.
43. 43 Pochart P, Dore J, Lemann F, et al. Interrelations between populations of methanogenic archaea and sulfate-reducing bacteria in the human colon. FEMS Microbiol Lett 1992;98: 225-8.
44. 44 Devereux R, Delaney M, Widdel F, et al. Natural relationships among sulfate-reducing cubacteria. J Bacteriol 1989;171:6689-95.
45. 45 Durand M, Bernalier A. Reductive acetogenesis in animal and human gut. In Physiological and clinical aspects of short-chain fatty acids. Cambridge: Cambridge University Press, 1995:107-17.
46. 11C] carbon dioxide by the microflora of human feces. Appl Environ Microbiol 1988;54:2723-7.
47. 47 Strocchi A, Ellis CJ, Levitt MD. Use of metabolic inhibitors to study hydrogen consumption by human feces: evidence for a pathway other than methanogenesis and sulfate reduction. J Lab Clin Med 1993;121:320-7.
48. 48 Strocchi A, Levitt MD. Factors affecting hydrogen production and consumption by human faecal flora. J Clin Invest 1992;89:1304-11.
49. 49 Strocchi A, Furne JK, Ellis CJ, et al. Competition for hydrogen by human faecal bacteria: evidence for the predominance of methane producing bacteria. Gut 1991;32:1498-501.
50. 50 Strocchi A, Furne J, Ellis C, et al. Methanogens outcompete sulphate reducing bacteria for hydrogen in the human colon. Gut 1994;35:1098-101.
51. 51 Strocchi A, Ellis CJ, Furne JK, et al. Study of constancy of hydrogen-consuming flora of human colon. Dig Dis Sci 1994;39:494-7.
52. 52 Levine J, Ellis CJ, Furne JK, et al. Sulfate reducing bacteria and ulcerative colitis [abstract]. Gastroenterology 1996;110: A949.
53. 53 Tsai HH, Sunderland D, Gibson GR, et al. A novel mucin sulphatase from human faeces: its identification, purification and characterization. Clin Sci 1992;82:447-54.
54. 54 Tsai HH, Dwarakanath AD, Hart CA, et al. Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment. Gut 1995;36:570-6.
55. 55 Pullan RD, Thomas GAO, Rhodes M, et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994;35:353-9.
56. 56 Lauritsen K, Hansen J, Bytzer P, et al. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984;25:1271-8.
57. 57 Laursen LS, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1271-6.
58. 58 Mardini HA, Lindsay DC, Deighton CM, et al. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut 1987;28:1084-9.
59. 59 Pitcher MCL, Gibson GR, Neale G, et al. Gentamicin kills multiple drug-resistant sulfate-reducing bacteria in patients with ulcerative colitis [abstract]. Gastroenterology 1994;106:A753.
60. 60 Newport PJ, Nedwell DB. The mechanisms of inhibition of Desulfovibrio and Desulfotomaculum species by selenate and molybdate. J Appl Bacteriol 1988;65:419-23.
61. 61 Taylor BF, Oremland RS. Depletion of adenosine triphosphate in Desulfovibrio by oxyanions of Group VI elements. Curr Microbiol 1979;3:101-3.
62. 62 Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci 1990;78: 119-25.
63. 63 Travis SPL, Jewell DP. Salicylates for ulcerative colitis -their mode of action. Pharm Ther 1904;63:135-61.
64. 64 Moore J, Babidge W, Millard S, et al. Colonic luminal hydrogen sulfide is not elevated in ulcerative colitis. Dig Dis Sci 1998;43:162-5.
65. 65 Andrews JC. Reduction of certain sulfur compounds to hydrogen sulfide by the intestinal microorganisms of the dog. J Biol Chem 1937;122:687-92.
66. 66 Denis W, Reed L. The action uf blood on sulfides. J Biol Chem 1926;72:385-93.
67. 67 Florin TH. Hydrogen sulphide and total acid-volatile sulphide in faeces, determined with a direct spectrophotometric method. Clin Chim Acta 1991;196:127-34.
68. 68 Roediger WEW, Duncan A. 5-ASA decreases colonic sulfide formation: implications for ulcerative colitis. Med Sci Res 1996;24:27-9.
69. 69 Levine J, Ellis CJ, Furne JK, et al. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 1998;93: 83-7.
70. 70 Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol 1992;72:57-64.
71. 71 Tragnone A, Valpiani D, Miglio F, et al. Dietary habits as risk factors for inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995;7:47-51.
72. 72 Roediger. Low protein diet in ulcerative colitis. Lancet 1998; 351:1555.
73. 73 Gibson GR, Macfarlane S, Macfarlane GT. Metabolic interactions involving sulphate-reducing and methanogenic bacteria in the human large intestine. FEMS Microbiol Ecol 1993;12:117-25.
74. 74 Dziewiatkowski DD. Fate of ingested sulfide sulfur labeled with radioactive sulfur in the rat. J Biol Chem 1945;161: 723-9.
75. 75 Curtis CG, Bartholomew FC, Rose FA, et al. Detoxification of sodium S-sulphide in the rat. Biochem Pharmacol 1973;21:2313-21.
76. 76 Weiseger RA, Pinkus LM, Jakoby WB. Thiol-S-methyltransferase: suggested role in detoxification of intestinal hydrogen sulphide. Biochem Pharmacol 1980;29: 2885-7.
77. 77 Pitcher MCL, Beatty ER, Harris RM, et al. Sulfur metabolism in ulcerative colitis investigation of detoxification enzymes in peripheral blood. Dig Dis Sci 1998;43:2080-5.